Home

Melvin K Spigelman

CIK 1339901 · last filed 2026-03-23

Melvin K Spigelman is a corporate insider who has filed 31 SEC Form 4 insider transactions across 4 companies since 2007. The most recent filing, for ANTX, was dated Mar 23, 2026. Across all open-market trades the lifetime net is −$1.6M, making them a net seller over the disclosed history. 13 SEC filings were submitted jointly with SYNERGY PHARMACEUTICALS, INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

4

Total Filings

31

Lifetime Open-Market Net

-$1.61M

Filer Profile

Reported Address
4655 DOUGLAS AVENUE
BRONX, NY 10471
Related Filers
SYNERGY PHARMACEUTICALS, INC. — 13 joint filings, latest 2018-08-16
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ANTX Director — $5.41 — $0 6 2026-03-23
SYNERGY PHARMACEUTICALS, INC. (SGYP) Delisted Director 48,305 — — $0 3 2018-08-16
MEDICINES CO /DE (MDCO) Delisted Director 60,633 — — -$1.61M 14 2018-05-29
SYNERGY PHARMACEUTICALS, INC. (SGYPW) Delisted Director — — — $0 8 2016-06-29

Recent Filings

31 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-03-23 ANTX Mixed — $0 EDGAR
2026-02-23 ANTX Grant (A) — $0 EDGAR
2025-05-23 ANTX Grant (A) — $0 EDGAR
2024-06-21 ANTX Grant (A) — $0 EDGAR
2023-06-09 ANTX Grant (A) — $0 EDGAR
2022-05-16 ANTX Grant (A) — $0 EDGAR
2018-08-16 SYNERGY PHARMACEUTICALS, INC. (SGYP) Delisted Mixed +48,305 $180.0K EDGAR
2018-06-19 SYNERGY PHARMACEUTICALS, INC. (SGYP) Delisted Grant (A) — $0 EDGAR
2018-05-29 MEDICINES CO /DE (MDCO) Delisted Mixed — -$104.3K EDGAR
2017-06-30 SYNERGY PHARMACEUTICALS, INC. (SGYP) Delisted Mixed — $0 EDGAR
Showing 1–10 of 31
Page 1 of 4
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.